Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418)

A multicenter case-controlled study

Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon Joo Kim, Eun Sook Lee, Keun Seok Lee, Han Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yongbae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung Sik Lee & 2 others Jung Soo Kim, Jihye Cha

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. Materials and Methods We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups. Results A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI. Conclusion We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Original languageEnglish
Pages (from-to)970-980
Number of pages11
JournalCancer Research and Treatment
Volume49
Issue number4
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Segmental Mastectomy
Anthracyclines
Breast
Breast Neoplasms
Lymph Nodes
Drug Therapy
Radiotherapy
Neoplasm Metastasis
Disease-Free Survival
Survival
taxane
Radiation Pneumonitis
Propensity Score
Lymphedema
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Haeyoung ; Park, Won ; Yu, Jeong Il ; Choi, Doo Ho ; Huh, Seung Jae ; Kim, Yeon Joo ; Lee, Eun Sook ; Lee, Keun Seok ; Kang, Han Sung ; Park, In Hae ; Shin, Kyung Hwan ; Wee, Chan Woo ; Kim, Kyubo ; Park, Kyung Ran ; Kim, Yongbae ; Ahn, Sung Ja ; Lee, Jong Hoon ; Kim, Jin Hee ; Chun, Mison ; Lee, Hyung Sik ; Kim, Jung Soo ; Cha, Jihye. / Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418) : A multicenter case-controlled study. In: Cancer Research and Treatment. 2017 ; Vol. 49, No. 4. pp. 970-980.
@article{9d83facb4b2c4b0b9230554fd4cbde27,
title = "Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418): A multicenter case-controlled study",
abstract = "Purpose This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. Materials and Methods We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups. Results A total of 41 patients (7.6{\%}) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4{\%} versus 92.6{\%} (p=0.50) and 95.1{\%} versus 94.5{\%} (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI. Conclusion We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.",
author = "Haeyoung Kim and Won Park and Yu, {Jeong Il} and Choi, {Doo Ho} and Huh, {Seung Jae} and Kim, {Yeon Joo} and Lee, {Eun Sook} and Lee, {Keun Seok} and Kang, {Han Sung} and Park, {In Hae} and Shin, {Kyung Hwan} and Wee, {Chan Woo} and Kyubo Kim and Park, {Kyung Ran} and Yongbae Kim and Ahn, {Sung Ja} and Lee, {Jong Hoon} and Kim, {Jin Hee} and Mison Chun and Lee, {Hyung Sik} and Kim, {Jung Soo} and Jihye Cha",
year = "2017",
month = "1",
day = "1",
doi = "10.4143/crt.2016.382",
language = "English",
volume = "49",
pages = "970--980",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Kim, H, Park, W, Yu, JI, Choi, DH, Huh, SJ, Kim, YJ, Lee, ES, Lee, KS, Kang, HS, Park, IH, Shin, KH, Wee, CW, Kim, K, Park, KR, Kim, Y, Ahn, SJ, Lee, JH, Kim, JH, Chun, M, Lee, HS, Kim, JS & Cha, J 2017, 'Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418): A multicenter case-controlled study', Cancer Research and Treatment, vol. 49, no. 4, pp. 970-980. https://doi.org/10.4143/crt.2016.382

Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418) : A multicenter case-controlled study. / Kim, Haeyoung; Park, Won; Yu, Jeong Il; Choi, Doo Ho; Huh, Seung Jae; Kim, Yeon Joo; Lee, Eun Sook; Lee, Keun Seok; Kang, Han Sung; Park, In Hae; Shin, Kyung Hwan; Wee, Chan Woo; Kim, Kyubo; Park, Kyung Ran; Kim, Yongbae; Ahn, Sung Ja; Lee, Jong Hoon; Kim, Jin Hee; Chun, Mison; Lee, Hyung Sik; Kim, Jung Soo; Cha, Jihye.

In: Cancer Research and Treatment, Vol. 49, No. 4, 01.01.2017, p. 970-980.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418)

T2 - A multicenter case-controlled study

AU - Kim, Haeyoung

AU - Park, Won

AU - Yu, Jeong Il

AU - Choi, Doo Ho

AU - Huh, Seung Jae

AU - Kim, Yeon Joo

AU - Lee, Eun Sook

AU - Lee, Keun Seok

AU - Kang, Han Sung

AU - Park, In Hae

AU - Shin, Kyung Hwan

AU - Wee, Chan Woo

AU - Kim, Kyubo

AU - Park, Kyung Ran

AU - Kim, Yongbae

AU - Ahn, Sung Ja

AU - Lee, Jong Hoon

AU - Kim, Jin Hee

AU - Chun, Mison

AU - Lee, Hyung Sik

AU - Kim, Jung Soo

AU - Cha, Jihye

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. Materials and Methods We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups. Results A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI. Conclusion We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

AB - Purpose This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. Materials and Methods We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups. Results A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI. Conclusion We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85030762165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030762165&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.382

DO - 10.4143/crt.2016.382

M3 - Article

VL - 49

SP - 970

EP - 980

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -